- Home
- BBOT vs IMTX Comparison
BBOT vs IMTX Comparison
Compare BBOT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$13.69
HOLD
Current Price
$10.18
Company Overview
Basic Information| Metric | BBOT | IMTX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBOT | IMTX |
|---|---|---|
| Price | $13.69 | $10.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $23.80 | $19.25 |
| AVG Volume (30 Days) | 168.9K | ★ 657.4K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $99,445,031.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.50 | $3.30 |
| 52 Week High | $14.78 | $12.41 |
Technical Indicators
Market Signals| Indicator | BBOT | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.02 |
| Support Level | N/A | $9.76 |
| Resistance Level | N/A | $12.41 |
| Average True Range (ATR) | 0.00 | 0.87 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 36.85 |
Price Performance
Historical Comparison BBOT
IMTX
About BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.